Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Journal of Clinical Pathways · 2018
DOI: 10.25270/jcp.2018.02.00001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pathways, 2018. Verfasst von Casey Mason und 10 weiteren Autor:innen. Beteiligte Einrichtung: Florida State University College of Medicine, Tallahassee, FL. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non-small cell lung cancer (NSCLC), there is evidence that testing has not been widely embraced in the clinical setting. This study uses clinical pathways to understand biomarker testing patterns and ensuing first-line treatment decisions. Data of patients with metastatic NSCLC were analyzed for testing rates and treatment selection at 7 cancer programs using data input by providers into the pathways software. Findings were analyzed by type of provider (community or academic). Among providers using clinical pathways, biomarker testing rates were high and appropriate selection of targeted therapy was observed. Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Florida State University College of Medicine, Tallahassee, FL.
- UPMC Cancer Center, Pittsburgh, PA.
- Via Oncology, Pittsburgh, PA.
- Tennessee Oncology, Nashville, TN.
- The Center for Cancer and Blood Disorders, Fort Worth, TX.
- University of Chicago Medicine, Chicago, IL.
Förderung
- NCI NIH HHS
Zitieren
APA
Mason, C., Ellis, P. G., Lokay, K., Barry, A., Dickson, N., Page, R., Polite, B., Salgia, R., Savin, M., Shamah, C., & Socinski, M. A. (2018). Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways. https://doi.org/10.25270/jcp.2018.02.00001
Vancouver
Mason C, Ellis PG, Lokay K, Barry A, Dickson N, Page R, et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways. 2018. doi:10.25270/jcp.2018.02.00001
BibTeX
@article{Mason2018,
author = {Mason, Casey and Ellis, Peter G and Lokay, Kathy and Barry, Amanda and Dickson, Natalie and Page, Ray and Polite, Blase and Salgia, Ravi and Savin, Michael and Shamah, Corey and Socinski, Mark A},
title = {Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting},
journal = {Journal of Clinical Pathways},
year = {2018},
doi = {10.25270/jcp.2018.02.00001}
}
EUVIMED